Home Managing quality vs. measuring uncertainty in the medical laboratory
Article
Licensed
Unlicensed Requires Authentication

Managing quality vs. measuring uncertainty in the medical laboratory

  • James O. Westgard
Published/Copyright: November 18, 2009

Abstract

ISO 15189's particular requirements for quality management in medical laboratories provide guidance for (a) relating performance specifications to the intended use of a test or examination procedure, (b) designing internal quality control (IQC) procedures to verify the attainment of the intended quality of test results, as well as (c) determining the uncertainty or results, where relevant and possible. This guidance has particular implications for analytical quality management, specifically for validating method performance relative to quality goals or requirements (intended use), designing statistical quality control procedures on the basis of the quality required for a test and the precision and bias observed for a method, and characterizing the quality achieved in practice by calculating measurement uncertainty. There already exists an error framework that provides practical tools and guidance for managing analytical quality, along with an existing concept of total error that can be used to characterize the quality of laboratory tests, thus there is considerable concern and debate on the merits and usefulness of measurement uncertainty. This paper argues that total error provides a practical top-down estimate of measurement uncertainty in the laboratory, and that the ISO/GUM model should be primarily directed to and applied by manufacturers.

Clin Chem Lab Med 2010;48:31–40.


Corresponding author: James O. Westgard, 7614 Gray Fox Trail, Madison, WI 53717, USA Phone: +1-608-833-4718, Fax: +1-608-833-0640,

Received: 2009-7-30
Accepted: 2009-7-30
Published Online: 2009-11-18
Published in Print: 2010-01-01

©2010 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorials
  2. Rapid diagnosis of swine-origin influenza A (H1N1) virus (S-OIV): useful or hype?
  3. Application of traceability concepts to analytical quality control may reconcile total error with uncertainty of measurement
  4. Reviews
  5. Pandemic influenza A (H1N1) 2009: the experience of the first six months
  6. The role of anti-core antibody response in the detection of occult hepatitis B virus infection
  7. Opinion Papers
  8. Managing quality vs. measuring uncertainty in the medical laboratory
  9. Collective opinion paper on findings of the 2009 convocation of experts on quality control
  10. General Clinical Chemistry and Laboratory Medicine
  11. Diagnostic performance of rapid influenza antigen assays in patients infected with the new influenza A (H1N1) virus
  12. Achieving continuous improvement in laboratory organization through performance measurements: a seven-year experience
  13. Evaluation of errors in a clinical laboratory: a one-year experience
  14. Validation and Outcome Studies
  15. Analytical validation of serum bone alkaline phosphatase (BAP OSTASE) on Liaison
  16. Analytical performance of the serum free light chain assay
  17. A study on the stability of urinary free catecholamines and free methyl-derivatives at different pH, temperature and time of storage
  18. Plasma nitrite/nitrate concentrations in patients with schizophrenia
  19. Inverse relationship between serum high density lipoprotein and negative syndrome in antipsychotic-naive schizophrenia
  20. Reference Values and Biological Variations
  21. Biological variation of free plasma amino acids in healthy individuals
  22. Differences in serum potassium concentrations between Chinese, Indians and Malays
  23. Determination of median levels of the free β subunit of human chorionic gonadotropin in women from mainland China using a new time-resolved fluoroimmunoassay
  24. Age- and gender-specific reference ranges for serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations on the Immulite 2500: results of the Study of Health in Pomerania (SHIP)
  25. Cardiovascular Diseases
  26. Improvement of the cardiac marker N-terminal-pro brain natriuretic peptide through adjustment for renal function: a stratified multicenter trial
  27. Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness
  28. Letters to the Editor
  29. Serum total and free sialic acid in patients with chronic liver disease
  30. Measurement of nitrotyrosine in plasma by immunoassays is fraught with danger: commercial availability is no guarantee of analytical reliability
  31. Problems with the determination of nitrotyrosine in human plasma are not solved in a satisfactory way and conclusions from clinical trials need to be carefully revised
Downloaded on 6.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2010.024/pdf
Scroll to top button